Janus Henderson Group PLC Raises Position in Disc Medicine, Inc. (NASDAQ:IRON)

Janus Henderson Group PLC grew its stake in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 68.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 749,827 shares of the company's stock after acquiring an additional 303,954 shares during the period. Janus Henderson Group PLC owned about 2.52% of Disc Medicine worth $36,828,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. California State Teachers Retirement System grew its holdings in Disc Medicine by 37.2% during the first quarter. California State Teachers Retirement System now owns 11,800 shares of the company's stock valued at $735,000 after purchasing an additional 3,200 shares during the period. SG Americas Securities LLC lifted its stake in shares of Disc Medicine by 44.2% during the 2nd quarter. SG Americas Securities LLC now owns 4,071 shares of the company's stock valued at $183,000 after buying an additional 1,247 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Disc Medicine by 89.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 51,050 shares of the company's stock valued at $2,301,000 after buying an additional 24,094 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Disc Medicine in the second quarter worth $129,000. Finally, Rhumbline Advisers boosted its stake in Disc Medicine by 86.2% in the 2nd quarter. Rhumbline Advisers now owns 24,447 shares of the company's stock worth $1,102,000 after purchasing an additional 11,315 shares during the period. Hedge funds and other institutional investors own 83.70% of the company's stock.

Insider Activity at Disc Medicine

In other news, Director William Richard White sold 7,136 shares of the stock in a transaction on Monday, November 4th. The stock was sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider William Jacob Savage sold 14,183 shares of the firm's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $65.45, for a total value of $928,277.35. Following the completion of the transaction, the insider now owns 40,405 shares in the company, valued at approximately $2,644,507.25. This trade represents a 25.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,836 shares of company stock worth $2,038,816 over the last quarter. Company insiders own 4.24% of the company's stock.

Disc Medicine Stock Up 4.0 %

Shares of IRON traded up $2.51 during trading hours on Friday, hitting $64.82. The company had a trading volume of 181,395 shares, compared to its average volume of 267,091. Disc Medicine, Inc. has a 52-week low of $25.60 and a 52-week high of $77.60. The stock's 50 day moving average price is $55.65 and its 200 day moving average price is $48.50. The firm has a market cap of $1.93 billion, a P/E ratio of -16.29 and a beta of 0.76.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.15. On average, research analysts expect that Disc Medicine, Inc. will post -4.05 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IRON has been the subject of several analyst reports. Morgan Stanley raised shares of Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 price target for the company in a report on Tuesday, November 5th. Cantor Fitzgerald reiterated an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a research report on Tuesday, October 15th. Wells Fargo & Company began coverage on shares of Disc Medicine in a report on Thursday, August 22nd. They issued an "overweight" rating and a $75.00 price target on the stock. Jefferies Financial Group initiated coverage on shares of Disc Medicine in a report on Wednesday, October 23rd. They set a "buy" rating and a $89.00 price objective for the company. Finally, HC Wainwright raised their price target on Disc Medicine from $70.00 to $118.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Disc Medicine has an average rating of "Buy" and an average price target of $85.80.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.